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ABSTRACT
Background: Women who suffer from breast cancer and type II diabetes with 
associated hyperglycaemia respond less well to chemotherapy. We have shown that 
hyperglycaemia induces resistance to chemotherapy through upregulation of fatty 
acid synthase (FASN) in breast cancer cells and increased insulin-like binding protein 
2 (IGFBP-2) in prostate cancer cells. As a tumour develops the tumour mass can 
outgrow the blood supply resulting in the cancer cells being exposed to hypoxia that 
stimulates many tumorigenic signalling pathways.
Methods: We used MCF-7 and T47D breast cancer cell lines. Trypan blue dye 
exclusion assay was employed to assess cell death and Western immunoblotting 
was used to determine changes in protein abundance. Hypoxia was induced both 
chemically by the addition of cobalt chloride (CoCl2) and using a hypoxia chamber.
Results: IGFBP-2 abundance increased with increasing concentrations of glucose 
(0-25 mM) that contributed to hyperglycaemia-induced chemo-resistance as it was 
abrogated by downregulating IGFBP-2 using siRNA. Production of IGFBP-2 is ER 
dependent: pre-treatment of MCF-7 cells with β-estradiol increased IGFBP-2 and 
induced chemo-resistance to doxorubicin. The hyperglycaemia-induced chemo-
resistance and increases in FASN and IGFBP-2 were negated in a hypoxic environment, 
with levels of cell death unaffected by glucose concentrations.
Conclusions: The sensitivity of breast cancer cells to chemotherapy is reduced 
in hyperglycaemic conditions but this effect is negated by hypoxia. These effects 
appear to be mediated via regulation of IGFBP-2 and FASN. Understanding the role 
of FASN and IGFBP-2 in chemo-resistance could provide a novel target for improving 
the effectiveness of breast cancer treatment.
INTRODUCTION
Cancer is complex and its initiation and progression 
involves many factors including genetic and environmental 
influences that include lifestyle. Accumulating 
epidemiological studies have suggested that there is a positive 
association between obesity, hypernutrition and increased risk 
of cancer. Over the past two decades, an estimation of 14% of 
all cancer mortality in men and 20% in woman are attributed 
to obesity and overweight, respectively [1]. In recent decades, 
increased caloric intake and reduced energy expenditure have 
increasingly become the general lifestyle in many different 
countries [2]. Adipose tissue in obesity exhibits significant 
changes in hormone secretion, adipokine, and cytokine 
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production. Obesity is also associated with insulin resistance, 
type 2 diabetes, atherosclerosis and hyperglycaemia. High 
concentrations of insulin and glucose promote growth and 
survival of malignant cells [3]. Cancer cells favour high 
glucose concentrations and glycolytic metabolism, which 
provide tumour cells with intrinsic growth stimulation 
and anti-apoptotic mechanisms under the influence of the 
Warburg effect [4].
IGFBP-2 is an essential regulator of the IGF 
axis. IGFBP-2 is one of the most abundant IGFBPs 
and its importance lies, at least in part, in its ability 
to modulate the bioavailability of IGF-I and –II [5]. 
IGFBP-2 can however also act independently of IGFs 
and there is evidence suggesting that IGFBP-2 activates 
intrinsic signalling cascades through its Arg-Gly-Asp 
(RGD) motif and the interaction with integrin receptors, 
in particular the α5β1 integrin [6]. The expression 
of IGFBP-2 is positively associated with tumour 
progression in various types of cancers. Elevated serum 
levels of IGFBP-2 and abundance of IGFBP-2 in solid 
tumours has been reported in a variety of malignancies 
including breast [7], prostate [8], lung [9], and colon 
[10]. Other studies have shown that glucose metabolism 
greatly influences the expression of IGFBP-2. This 
was shown in prostate cancer cells where IGFBP-2 
transcription was induced in high glucose due to 
acetylation of histones H3 and H4 associated with 
the Igfbp-2 promoter region. This upregulation also 
influenced the ability of the cancer cells to respond to 
treatments and induced resistance to chemotherapy in 
hyperglycaemic conditions [11].
Glucose serves as a substrate for fatty acid synthase 
(FASN) and FASN is highly expressed in malignant cells 
including breast cancer [12]. We and others have shown that 
silencing FASN using siRNA leads to improved sensitivity 
of breast cancer cells to chemotherapy [13, 14]. Our 
previous studies have shown that the expression of FASN 
is higher in malignant cells compared to non-malignant 
cells [14]. In addition, inhibition of FASN eliminates the 
survival effects conferred by high glucose against cell death 
induced by both paclitaxel and 5-fluorouracil in MCF-7 and 
T47D breast cancer cells indicating that FASN might be a 
mediator in the pathway of resistance to chemotherapies in 
a hyperglycaemic environment.
Numerous studies have reported that hypoxia 
contributes to many human diseases. The effect of 
hypoxia is chiefly mediated by the transcription factor 
hypoxia inducible factor-I (HIF-I). HIF-I is composed of 
two subunits, HIF-Iα and HIF-Iβ. The stability of HIF-
Iα determines its transcriptional activity. Under hypoxia, 
HIF-Iα is stabilised and translocated to the nucleus where 
it regulates the expression of many genes [15]. Hypoxia 
influences many biological functions including cell 
proliferation, angiogenesis, apoptosis and insulin resistance 
[16, 17]. Accumulating evidence suggests that adipose 
tissue in obese individuals receives an inadequate supply 
of oxygen, leading to the induction of HIF-Iα [18, 19]. 
Moreover, the blood flow in subcutaneous adipose tissue is 
lowered in obese people compared to lean people [20]. Also, 
the natural rapid diet-induced increase in subcutaneous 
blood flow [21] is significantly reduced or even diminished 
in obese individuals [20]. All these factors contribute to a 
potentially higher exposure to hypoxia.
Obesity is associated with various metabolic 
dysfunctions including insulin resistance, type 2 diabetes, and 
elevated levels of glucose in the blood [3]. Obesity initiates 
insulin resistance, which triggers two cancer-promoting 
factors; hyperinsulinemia and hyperglycaemia. Sustained 
insulin resistance leads to hyperglycaemia that subjects cells 
including tumour cells to abnormally high concentrations of 
glucose. High levels of insulin and glucose positively drive 
cancer cell growth and survival. That is because tumour cells 
favour glycolytic metabolism [4], utilising high glucose 
as a fuel for survival. In this study, we aimed to assess the 
impact of hypoxia on the sensitivity of breast cancer cells 
to chemotherapy and its effect on hyperglycaemia-induced 
chemo-resistance and the underlying mechanisms.
RESULTS
Glucose increases IGFBP-2 at the protein and 
mRNA levels
To investigate the effect of glucose on the 
abundance of IGFBP-2, breast cancer cells MCF-7 and 
T47D were exposed to different levels of glucose (5mM, 
9mM and 25mM) and the levels of IGFBP-2 secreted into 
the media and within the cells was examined by Western 
immunoblotting.
MCF-7 cells exhibited an approximate 4-fold increase 
in secreted IGFBP-2 levels at 9mM and 25mM glucose 
compared to 5mM glucose (Figure 1A and 1C). Cellular 
IGFBP-2 also increased approximately 1.5 fold at 25mM 
glucose compared to 5mM glucose (Figure 1B and 1D). 
T47D cells showed a similar pattern to MCF-7 cells in that 
IGFBP-2 abundance increased in response to glucose. At 
9mM and 25mM glucose, secreted IGFBP-2 showed an 
approximate one-fold increase at 9mM and 25mM glucose 
compared to 5mM glucose (Figure 1E and 1G). Endogenous 
IGFBP-2 also increased at 9mM and 25mM glucose by 
approximately 2.5 and 4 fold, respectively, compared to 
5mM glucose (Figure 1F and 1H).
To determine whether the glucose-induced secretion 
was regulated at the transcriptional level in addition to the 
protein level, the mRNA expression of IGFBP-2 in MCF-
7 and T47D cells was determined using real-time PCR. 
Glucose increased IGFBP-2 expression by approximately 
1.2 fold (P<0.05) in 25mM glucose compared to 5mM 
glucose in MCF-7 cells (Figure 1I), and a greater response 
was observed in T47D cells where IGFBP-2 expression 
increased approximately 1.4 fold (P<0.01) in 9mM glucose 
and 1.5 fold (P<0.01) in 25mM glucose (Figure 1J).
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Figure 1: IGFBP-2 increases in response to different glucose levels. MCF-7 cells were treated with 5, 9, and 25mM glucose for 
48h and the abundance of secreted (A) and endogenous (B) IGFBP-2 was examined by Western immunoblotting. The optical densitometry 
measurements of IGFBP-2 secreted (C) and in lysates (D) in MCF-7 cells. T47D cells were treated with 5, 9, and 25mM glucose for 
48h and the abundance of secreted (E) and in lysates (F) IGFBP-2 was examined by Western immunoblotting. The optical densitometry 
measurements of IGFBP-2 secreted (G) and in lysates (H) in T47D cells. (I) MCF-7 cells were seeded at 0.4x106 cells in 5mM glucose 
growth medium for 24h prior to switching to SFM of different glucose concentrations 5, 9, and 25mM glucose for 24h. The cells were lysed 
with Trizol and the level of IGFBP-2 mRNA expression was determined by real-time PCR. (J) T47D cells were treated the same way as 
MCF-7 cells in 5, 9, and 25mM glucose for 24h, and the level of IGFBP-2 expression was determined by real-time PCR. 18S was used a 
internal housekeeping gene. The graphs represent the mean±SEM of three independent repeats each conducted in triplicate.
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Previously, we reported that in prostate cancer cells 
glucose increased resistance to chemotherapy through 
upregulating IGFBP-2 [11]. Increased acetylation of 
histones associated with the Igfbp-2 gene promoter in 
hyperglycaemic conditions was associated with increased 
IGFBP-2 transcription and induced chemo-resistance 
[11]. This glucose mediated regulation of IGFBP-2, 
however, was different in breast cancer cells. The histones 
associated with Igfbp-2 gene promoter were not acetylated 
or de-methylated by high glucose suggesting that the 
hyperglycaemic induction of IGFBP-2 was via alternative 
mechanisms (data not shown).
Does the glucose-induced increase in IGFBP-2 
contribute to hyperglycaemia-induced chemo-
resistance?
Having determined that glucose increased the levels 
of IGFBP-2 both at the protein and mRNA levels in breast 
cancer cells, the role of IGFBP-2 in the response of breast 
cancer cells to chemotherapy was investigated.
MCF-7 cells were transfected with IGFBP-2 siRNA 
to silence its expression and then were grown in different 
glucose concentrations (5mM, 9mM and 25mM glucose) 
prior to treatment with doxorubicin. MCF-7 cells acquired 
resistance to doxorubicin in 9mM and 25mM glucose 
and the level of cell death decreased from 60% at 5mM 
glucose to 39.6% at 9mM glucose (P<0.01) and 37.7% at 
25mM glucose (P<0.01) for MCF-7 cells. However, this 
glucose-induced resistance to chemotherapy was negated 
when IGFBP-2 was silenced. Sensitivity to doxorubicin 
was restored in MCF-7 cells and the level of cell death 
was similar in all levels of glucose at 66% cell death 
in 9mM and 25mM glucose compared to 68% in 5mM 
glucose (Figure 2A). The transfection with IGFBP-2 
siRNA was successful in suppressing IGFBP-2 production 
as indicated in the insert of Figure 2. These data suggest 
that IGFBP-2 plays a significant role in how the breast 
cancer cells respond to chemotherapy in a hyperglycemic 
environment. These findings were further confirmed in 
T47D cells where the hyperglycemia-induced chemo-
resistance was also negated when IGFBP-2 expression 
was silenced (Figure 2B).
Investigation of the response of MCF-7 cells to 
chemotherapy following addition of recombinant 
IGFBP-2
Having shown that IGFBP-2 plays a role in 
hyperglycaemia-induced chemo-resistance, adding 
exogenous recombinant IGFBP-2 to breast cancer cells 
and monitoring their response to chemotherapy was 
performed to further investigate the effect of IGFBP-2 on 
survival.
Glucose exerted a protective effect on cell survival 
as treating MCF-7 cells with doxorubicin induced more 
cell death in 5mM glucose, 60.1% compared to 44.2% in 
9mM and 37.9% in 25mM glucose. The level of cell death 
was reduced further in all three glucose concentrations to 
approximately 34.6% when the cells where treated with 
exogenous human recombinant IGFBP-2 (Figure 3A). 
Similar to MCF-7 cells, T47D cells were more resistant 
to doxorubicin in 9mM and 25mM glucose compared 
to 5mM glucose. The level of cell death was 60.0% in 
5mM glucose and much lower at 43.8% in 9mM and 
41.5% in 25mM glucose. This doxorubicin-induced cell 
death was decreased when the cells were treated with 
exogenous IGFBP-2. The level of cell death dropped 
significantly in 5mM glucose from 60.0% to 38.9% upon 
IGFBP-2 treatment. The levels of cell death in 9mM and 
25mM glucose were not significantly different at 37.4% 
and 35.7%, respectively (Figure 3B). This confirms that 
IGFBP-2 is protective against doxorubicin-induced cell 
death. This is consistent with the data that shows the 
involvement of IGFBP-2 in altered sensitivity of cancer 
cells to chemotherapy when IGFBP-2 expression is 
silenced. Having shown previously that IGFBP-2 is a 
negative regulator of PTEN that leads to increased Akt 
activation (see Supplementary Figure 2) [22], we also 
show that high glucose is associated with an anticipated 
increase in p-Akt consistent with our previous data. 
(Supplementary Figure 1).
Estrogen-induced IGFBP-2 secretion is regulated 
by nuclear ERs but not membrane ERs
Estrogen receptors (ERs) are an essential group of 
receptors, which can vary in the protein conformation, 
location and function. There are two forms of ERs, nuclear 
ERs, members of the intracellular receptor family, mainly 
consisting of ERα and ERβ, and membrane ERs some 
of which belong to G-protein coupled receptors [23]. In 
this study, two forms of 17β-estradiol were used: human 
17β-estradiol and 17β-estradiol conjugated with BSA. 
The former binds to all ERs whereas the conjugated 
17β-estradiol with BSA is not internalized by cells and can 
only bind to ER found on the cell surface, i.e. membrane 
ERs. The estrogen receptor is a regulator of IGFBP-2 [22], 
and it is well known that 17β-estradiol via the nuclear 
ERα regulates IGFBP-2 but we wished to assess if there 
was also a contribution from 17β-estradiol activity via 
membrane receptors.
Treatment with 17β-estradiol induced IGFBP-2 
secretion in 5mM glucose from 8.4ng/ml to its highest 
10.6ng/ml at 0.1nM and 1nM 17β-estradiol. Similarly in 
25mM glucose IGFBP-2 concentrations increased from 
11.4ng/ml to approximately 13.6ng/ml at 0.1nM and 1nM 
17β-estradiol, and up to 14.7ng/ml at 10nM 17β-estradiol 
(Figure 4A). Treating the cells with the conjugated form 
of 17β-estradiol had no effect on IGFBP-2 secretion 
(Figure 4B). These data suggest that the estrogen-induced 
increase in IGFBP-2 is probably controlled mainly through 
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Figure 2: The role of IGFBP-2 in hyperglycaemia-induced chemo-resistance. MCF-7 cells (A) and T47D cells (B) were 
incubated in different glucose conditions (5mM, 9mM and 25mM) and treated in the presence and absence of IGFBP-2 siRNA. The cells 
were treated with 1μM doxorubicin. Cell death was measured by a trypan blue dye exclusion assay. Inserts: IGFBP-2 abundance in 5, 9, 
25mM glucose in the presence and absence of IGFBP-2 siRNA where the total cell extract was analysed by Western immunoblotting. The 
graph represents the mean±SEM of three independent repeats each conducted in triplicate; NS= non-silencing siRNA, BP2= IGFBP-2 
siRNA.
Oncotarget74640www.impactjournals.com/oncotarget
nuclear estrogen receptors and not via membrane estrogen 
receptors.
Nuclear ERs increase IGFBP-2 secretion that 
is associated with an increase in FASN and is 
protective against chemotherapy
Having shown that IGFBP-2 is involved in 
hyperglycaemia-induced chemo-resistance and that 
IGFBP-2 secretion was also induced by activation of 
nuclear ERs, we then investigated the effect of inducing 
IGFBP-2 secretion in breast cancer cells by estrogen 
and then monitoring their response to chemotherapy. 
MCF-7 cells were treated with 1nM 17β-estradiol in 
5mM and 25mM glucose then dosed with doxorubicin. 
Treating MCF-7 cells with 17β-estradiol enhanced 
cell survival in response to doxorubicin, which was 
associated with an increase in IGFBP-2 secretion 
induced by 17β-estradiol. The levels of cell death in 
5mM glucose was reduced to a level similar to the level 
of cell death in 25mM glucose under 17β-estradiol 
treatment (Figure 5A and 5B). This would be consistent 
with IGFBP-2 playing a protective role in inducing 
resistance to chemotherapy in hyperglycaemic 
conditions.
We have previously shown that FASN contributes 
to hyperglycaemia-induced chemo-resistance [14]. 
We have also shown that the increase in FASN in 
hyperglycaemic conditions was associated with 
an increase in the phosphorylation and nuclear 
translocation of ER via the MAPK pathway [24]. In 
this study we have examined whether this increase 
in IGFBP-2 through nuclear ERs involves the FASN 
pathway. Consistent with our previous data, FASN 
abundance increased in 25mM glucose compared to 
5mM glucose, and this increase was further enhanced 
under 17β–estradiol treatment. This increase in FASN 
after 17β–estradiol treatment might contribute to the 
reduction seen in cell death induced by doxorubicin 
(Figure 5B, 5C and 5D).
Figure 3: Human recombinant IGFBP-2 promotes survival against chemotherapy in breast cancer cells. (A) MCF-7 
cells were seed at 0.1x106 cells then were treated with 100ng/ml human recombinant IGFBP-2 in 5mM, 9mM and 25mM glucose. The 
cells were exposed to 1μM doxorubicin for 24h and cell death was measured by a cell count and viability assay. (B) T47D cells were seed 
at 0.1x106 cells then were treated with 200ng/ml human recombinant IGFBP-2 in 5mM, 9mM and 25mM glucose. The cells were exposed 
to 5μM doxorubicin for 24h and cell death was measured by a cell count and viability assay. The graphs represent the mean±SEM of three 
independent repeats each conducted in triplicate.
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Hypoxia negates the hyperglycaemia-induced 
chemo-resistance
As the tumour develops, the tumor mass can 
frequently outgrow the blood supply resulting in the 
cells being exposed to hypoxia. Here, we investigated the 
effect of hypoxia on IGFBP-2 in breast cancer cells and 
how this affected chemo-sensitivity in euglycaemic and 
hyperglycaemic conditions.
Exposing MCF-7 cells to hypoxia reduced the 
abundance of IGFBP-2. Interestingly, the glucose-induced 
increase in IGFBP-2 was also negated under hypoxia 
induced by CoCl2 (Figure 6A and 6B).
Having established that hypoxia reduced the 
abundance of IGFBP-2, we further investigated the 
effect of this hypoxia-induced reduction in IGFBP-2 
on the response of breast cancer cells to chemotherapy. 
MCF-7 cells were exposed to hypoxia, using either 
CoCl2 or grown in a hypoxic chamber with 2% O2, in 
the presence and absence of doxorubicin in different 
glucose conditions (5mM, 9mM and 25mM glucose). In 
euglycaemic conditions the amount of cell death induced 
by doxorubicin was not affected by hypoxia.
Exposing MCF-7 cells to 25mM glucose in normal 
oxygenated conditions induced resistance to doxorubicin 
where levels of cell death were reduced from 78.5% in 
5mM glucose to 53.8% in 25mM glucose. Hypoxia 
induced by CoCl2 then negated this effect of high glucose 
on the response of MCF-7 cells to doxorubicin. The 
death induced by doxorubicin under hypoxia was not 
significantly different in both levels of glucose where cell 
death was 77.8% in 5mM glucose and 79.1% in 25mM 
glucose (Figure 6C). Similarly, incubating MCF-7 cells 
in 2% O2 negated the effect of hyperglycemia-induced 
chemo-resistance and increased cell death in 25mM 
glucose from 33.9% to 72.1% (Figure 6D). HIF-Iα was 
indicative of successful induction of hypoxia (Figure 
6E and 6F). Similar findings were observed in T47D 
cells (data not shown). This increase in cell death under 
hypoxia in high glucose was associated with a reduction 
in IGFBP-2 (Figure 6G), consistent with IGFBP-2 playing 
a role in hypoxia negating the effect of glucose-induced 
resistance to chemotherapy.
Hypoxia also down-regulates FASN, ERα and 
Akt activation
Previous studies in our laboratory have shown that 
IGFBP-2 is a novel regulator of the ERα, and that FASN 
and ERα overexpression in hyperglycaemic conditions 
contributes to chemo-resistance in breast cancer cells. 
IGFBP-2 has long been known to modulate IGF and 
Figure 4: The effect sensitizing ERs on IGFBP-2 secretion. MCF-7 cells were seeded at 0.0125x106 cells then were treated 
with various doses of 17β-estradiol and conjugated 17β-estradiol ranging from 0nM to 50nM for 24h. IGFBP-2 concentrations were 
determined by ELISA after treatment with 17β-estradiol (A) and conjugated 17β-estradiol (B) The graphs represents the mean±SEM of 
three independent repeats each conducted in triplicate (* P<0.05, *** P<0.001).
Oncotarget74642www.impactjournals.com/oncotarget
integrin signalling [25]. PI3K/Akt signalling pathway 
plays a fundamental role in IGFBP-2 stimulation in breast 
cancer [26]. Here, we investigated whether hypoxia 
impacted on FASN, ERα and Akt activation that we 
previously identified as important players (Supplementary 
Figure 2).
As before, high 25mM glucose increased the 
abundance of FASN, however this increase was negated 
Figure 5: Nuclear ERs increase IGFBP-2 levels that is protective against chemotherapy. (A) MCF-7 cells were seeded 
at 0.1x106 cells in 5mM growth medium then were serum starved for 24h in 5mM and 25mM glucose SFM. The cells were treated with 
17β-estradiol for 48h and doxorubicin was introduced in the last 24h of incubation. Trypan blue exclusion assay was used to determine the 
level of cell death. (B) Western immunoblotting showing changes in IGFBP-2 and FASN protein abundance in 5mM and 25mM glucose in 
the presence and absence of 17β-estradiol. Optical densitometry measurements of IGFBP-2 (C) and FASN (D) in response to 17β-estradiol 
in 5mM and 25mM glucose. The graphs represent the mean±SEM of three independent experiments each performed in triplicate.
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Figure 6: The effect of hypoxia on hyperglycaemia-induced chemo-resistance. (A) MCF-7 cells were treated with 500μM 
CoCl2. Changes in the abundance of IGFBP-2 was analysed using Western immunoblotting. (B) Densitometry measurements of IGFBP-2 
abundance in normoxic and hypoxic conditions in MCF-7 cells treated in 5mM and 25mM glucose. Hypoxia was chemically-induced in 
MCF-7 cells by 500μM CoCl2 (C) and b low levels of oxygen (2% O2) (D) in 5mM and 25mM glucose and the cells were treated with 
1μM doxorubicin for 24h. The rate of cell death was analysed using a trypan blue dye exclusion assay. HIF-Iα was used as an indicator 
of successful induction of hypoxia by 500μM CoCl2 (E) and 2% O2 (F) α-tubulin was used as a loading control. (G) Changes in IGFBP-2 
concentrations in MCF-7 cells treated in 5mM and 25mM glucose in the presence or absence of 500μM CoCl2 and 1μM doxorubicin 
determined using ELISA. The graph represents the mean±SEM of three independent repeats each conducted in triplicate.
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when the cells were exposed to hypoxia. FASN levels 
at both 5mM and 25mM glucose were reduced and the 
glucose-induced increase in FASN was completely 
negated (Figure 7A and 7B). Moreover, hypoxia also 
reduced the abundance of ERα in MCF-7 cells (Figure 
7A and 7C). In addition, Akt activation increased in 
25mM glucose, and this is consistent with the increase of 
IGFBP-2 seen in hyperglycaemia. The activity however 
was significantly reduced upon exposure to hypoxia. 
Hypoxia reduced the activity of Akt at both glucose levels 
and the glucose induced increase observed in 25mM 
glucose was completely negated (Figure 7A and 7D).
DISCUSSION
Hyperglycaemia is associated with metabolic 
imbalance and type 2 diabetes and has also been linked 
to a high risk of breast cancers. Patients who suffer from 
obesity and diabetes respond less well to chemotherapy 
[27]. Our previous study has shown that treating breast 
cancer cells with doxorubicin was less effective in 
high glucose compared to normal glucose levels [14]. 
These data were consistent with epidemiological 
studies where breast cancer patients with diabetes have 
poorer responsiveness to treatment [28]. In this study 
we used a range of glucose concentrations to represent 
euglycaemic (5mM), those of a well-controlled diabetic 
(9mM) and physiologically extreme (25mM) levels of 
glucose. Resistance to doxorubicin-induced apoptosis 
that correlated with an increase in IGFBP-2 abundance 
and secretion was observed at both high levels of glucose 
used in this study. This study assesses extremes of hypoxia 
and levels of glucose and presumably in different parts 
of the tumour the interaction between levels of glucose 
and hypoxia will be graded. Understanding the balance 
between hypoxia and hyperglycaemia during malignant 
transformation is important in identifying potential 
mechanistic targets/biomarkers: one of which could be 
IGFBP-2.
Studies conducted on oesophageal adenocarcinoma 
cells have also indicated that IGFBP-2 modulates the 
response of cells to chemotherapy [29]. In primary 
oesophageal carcinoma patients, increased expression 
of IGFBP-2 correlated with shorter disease-free lifespan 
and induced resistance to chemotherapy. Silencing 
the expression of IGFBP-2 restored the sensitivity 
of oesophageal carcinoma cells to cisplatin [29]. 
Modulation of IGFBP-2 expression was shown to 
increase proliferation, migration, and invasion suggesting 
that IGFBP-2 has metastatic potential. The study also 
highlighted that Akt and MAPK signalling pathways were 
implicated in the chemo-sensitization. IGFBP-2 stimulated 
activation of PI3K and MAPK by both IGF-dependent and 
independent mechanisms [29]. This study on oesophageal 
carcinoma cells was consistent with our studies on 
breast cancer cells. We have previously shown that 
hyperglycaemia-induced chemo-resistance is dependent 
on FASN and ERα phosphorylation and translocation to 
the nucleus. The phosphorylation of ERα was mediated 
by MAPK in high glucose [24]. Here, we have shown that 
estrogen increased the abundance of IGFBP-2 through 
nuclear ERα with little contribution from the membrane 
estrogen receptors. Silencing the expression of IGFBP-2 
using siRNA negated the hyperglycaemia-induced chemo-
resistance and restored the sensitivity of breast cancer cells 
to doxorubicin in high glucose.
Studies have suggested that IGFBP-2 has metabolic 
effects. Increased expression of IGFBP-2 has been 
correlated with poor blood glucose clearance. IGFBP-2 
harbours an integrin-binding domain Arg-Gly-Asp (RGD) 
that is involved in IGF-I independent effects [30]. This 
study examined whether or not high IGFBP-2 levels 
with an RGD motif would block glucose clearance after 
glucose oral administration. Transgenic mice that over-
expressed IGFBP-2 showed impaired glucose handling 
after an oral glucose tolerance test but mice expressing a 
mutant IGFBP-2 carrying an Arg-Gly-Glu (RGE) instead 
of an RGD motif showed no such deterioration in glucose 
handling. Moreover, lower levels of the glucose transporter 
proteins (Glut-4) were expressed on the plasma membrane 
of muscle tissue isolated from the transgenic mice after 
glucose administration. The low levels of Glut-4 were 
associated with impaired glucose tolerance. This study 
identified that elevated integrin-linked kinase and focal 
adhesion kinase levels were dependent on the existence 
of the RGD motif. The RGD motif was important for 
glucose clearance in IGFBP-2 transgenic mice and that 
Glut-4 expression was regulated by IGFBP-2 in an RGD-
dependent manner [30]. In this study we have shown that 
glucose-induced IGFBP-2 secretion promoted resistance 
of breast cancer cells to chemotherapy; whether or not the 
RGD motif in IGFBP-2 is responsible for these actions is 
still unclear and needs further investigation.
Our results have potential implications for cancer 
patients who suffer from type 2 diabetes, implying that 
rigorous control of their glucose levels might increase 
their responsiveness to chemotherapy. Supporting 
this is evidence suggesting that sufficient control of 
hyperglycaemia during chemotherapy could improve 
outcome of treatments in patients with haematological 
and solid tumours [31]. In addition, accumulating 
epidemiological and laboratory studies have reported 
that the use of antidiabetic therapy may improve 
responsiveness of cancer cells, enhanced effectiveness 
to chemotherapy, and reduce recurrence. Agents such as 
metformin have increasingly become of interest in cancer 
treatment; though the mechanisms of how these agents 
act and their anticancer effects are still being investigated 
and defined. Adding metformin to adjuvant breast 
chemotherapy in nondiabetic individuals reduced glucose 
levels, improved sensitivity to insulin and appeared to 
reduce subsequent metastasis [32]. In mice, reduction of 
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glucose levels by fasting prior to chemotherapy improved 
the outcome of therapy, lowered toxicity and reduced 
IGF-I levels [33]. Recently, our group has shown that 
metformin could restore the sensitivity of prostate cancer 
cells to docetaxel. Treating prostate cancer cells with 
docetaxel in hyperglycaemic conditions reduced cell death 
and induced resistance. This resistance against docetaxel 
was negated when the cells were treated with metformin 
and this was mediated by a reduction in the levels of 
IGFBP-2 [34].
As the tumour grows, the tumour cells can 
frequently outgrow the blood supply resulting in the 
cells being exposed to hypoxia. The results presented 
here indicate that in euglycaemic conditions exposure to 
Figure 7: The involvement of the FASN/ERα/Akt pathway in hypoxia regulation of IGFBP-2. (A) MCF-7 cells were seeded 
at 0.1x106 cells in 5mM growth medium. The cells were then treated in 5mM and 25mM glucose and were exposed to hypoxia. Changes 
in the abundance of HIF-Iα, FASN, ERα, Akt and p-Akt were analysed using Western immunoblotting. Densitometry measurements of 
changes in the abundance of FASN (B) ER (C) p-Akt/Akt (D) under normal and hypoxic conditions in 5mM and 25mM glucose. The graphs 
represent the mean±SEM of three independent repeats each conducted in triplicate.
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hypoxia does not affect the response of breast cancer cells 
to chemotherapy. In contrast, in hyperglycaemic conditions 
hypoxia can completely negate the hyperglycaemia-
induced resistance to chemotherapy. Although in many 
solid tumours cell metabolism is altered with an increase 
in glycolytic flux and a reduction in flux through the 
TCA cycle with reduced oxidative phosphorylation, 
often termed the Warburg effect. This effect is used 
clinically in an imaging technique, PET, to localise solid 
tumours. In the prostate cell metabolism is atypical and 
PET has proven of limited use for prostate cancer. Our 
results indicate that the effects of hyperglycaemia on 
chemosensitivity are probably dependent on oxidative 
phosphorylation. Our study has also shown that hypoxia 
reduces IGFBP-2 and FASN. Since FASN and IGFBP-2 
confer resistance to chemotherapy in high glucose, 
reducing FASN and IGFBP-2 abundance negated the effect 
of hyperglycaemia under hypoxia. Hyperglycaemia has 
been shown to impair the expression of a number of HIF 
family members. HIF-Iα repression by hyperglycaemia 
contributes to many complications in diabetes [35]. In 
non-small cell lung cancers, the ATP-dependent efflux of 
doxorubicin by P-glycoprotein (P-gp) has been reported 
to be one important mechanism for resistance. Increased 
expression of P-gp was associated with increased 
doxorubicin efflux and induced resistance to doxorubicin. 
Hypoxia negated this P-gp mediated resistance to 
doxorubicin via HIF-Iα signalling [36]. Since IGFBP-2 
expression and secretion is increased in high glucose and 
IGFBP-2 has a role in inducing resistance to chemotherapy 
in breast cancer cells, this may suggest that IGFBP-2 
might have an effect on P-gp, which would need to be 
investigated. In conclusion, the response of breast cancer 
cells to chemotherapy is dependent on the conditions of 
the tumour microenvironment. High glucose increased the 
abundance and expression of IGFBP-2 in breast cancer 
cells that led to reduced sensitivity to chemotherapy. The 
hyperglycaemia-induced chemo-resistance was negated 
by hypoxia and this was consistent with a reduction in 
IGFBP-2 levels.
MATERIALS AND METHODS
Compounds were purchased from Sigma-Aldrich, 
Dorset, UK unless otherwise stated.
Cell maintenance and treatment
Breast cancer cells MCF-7 and T47D, purchased 
from ATCC (Molsheim, France) were cultured and 
maintained in 4.5g glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 2mM L-glutamine. Upon 80% 
confluence, cells were detached from culture flasks using 
10% trypsin. The cells were serum starved for 24h in 
serum-free DMEM in normal (5mM), well-controlled 
diabetic (9mM), or uncontrolled severe hyperglycaemic 
(25mM) levels of glucose. Depending on the context 
of the experiment, the cells were treated with human 
recombinant IGFBP-2 (GroPep, Thebarton, Australia), 
17β-estradiol-water soluble, 17β-estradiol 6-(o-carboxy-
methyl) 31.20 mole steroid/mole BSA oxime:BSA, 
or doxorubicin hydrochloride. Hypoxia was induced 
chemically using 500μM CoCl2 or by the use of a hypoxia 
chamber set to 2% oxygen (O2) pressure.
Transfection with siRNA
IGFBP-2 siRNA was used as described previously 
[11]. The transfection kit was purchased from Synvolux 
Therapeutics (Leiden, The Netherlands) and transfection 
was conducted following the manufacturer’s instructions.
Trypan blue dye exclusion assay
Viable and dead cells were determined by trypan 
blue dye exclusion assay as described previously [14]. 
Dead cells were defined as those stained dark blue whereas 
live cells are bright white.
Protein analysis
Western immunoblotting was conducted to monitor 
changes in protein abundance, and band intensities were 
determined by ImageLab software as described by the 
manufacturer BioRad, Hertfordshire, UK. The membranes 
were probed with anti-FASN (mouse, 1:2000) and anti-
HIF-Iα (mouse, 1:500), purchased from BD Biosciences 
Oxford, UK, anti-ERα (mouse, 1:750) and anti-IGFBP-2 
(goat, 1:1000) from Santa Cruz Heidelberg, Germany, 
anti-Akt (rabbit, 1:1000) and anti-p-Akt (rabbit, 1:1000) 
purchased from Cell Signaling Hertfordshire, UK, and 
anti-α-tubulin (mouse, 1:5000) purchased from Merck 
Millipore Hertfordshire, UK. Depending on the species 
of the primary antibody, the blots were incubated in 
horseradish peroxidase-linked anti-mouse/rabbit/goat 
antibody (1:2000) purchased from Merck Millipore 
Hertfordshire, UK.
Quantitative real time polymerase chain reaction 
(qRT-PCR)
Breast cancer cells were exposed to different 
glucose levels (5mM, 9mM and 25mM glucose) for 24h 
prior to extraction of RNA as outlined previously [37]. 
18S was used as a housekeeping gene.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to estimate the concentration 
of secreted IGFBP-2 expressed in ng/ml as performed 
previously [11]. ELISA was performed following the 
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manufacturer’s instructions (DuoSet ELISA kit Human 
IGFBP-2, Abingdon, UK).
Statistical analysis
Data in this study represent the mean±SEM of three 
independent experiments. The standard curve of ELISA 
outputs followed a four parameter logistic (4-PL) curve fit. 
For multiple comparisons, one-way ANOVA post hoc LSD 
test was used to compare treated samples with controls 
using IBM SPSS Statistics 21 software. Differences 
between samples were considered significant at *P<0.05, 
**P<0.01, and ***P<0.001.
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